---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000159"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:18:51.056734+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiora expands KIO-301 Phase 2 development after positive ABACUS-1 results; Q3 net loss $5.8M

## Summary
- ABACUS-1 Phase 1b showed KIO-301 safe, tolerable, with significant visual field improvements and increased brain activity on fMRI.
- Company plans Phase 2 trials for RP (ABACUS-2), Choroideremia, and Stargardt disease in 2024.
- Q3 2023 net loss $5.8M vs $5.1M in Q3 2022; loss increase driven by non-cash impairment of KIO-101/201.
- Cash and equivalents $5.4M, plus $1.3M tax receivables; runway into May 2024; $9.6M available on equity line.
- Raised $6.3M in funding and $1.2M in tax incentives during first half of 2023.

## SEC filing metadata
- accession: 0001372514-23-000159
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000159/0001372514-23-000159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000159/kprx-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000159
- JSON: https://secwatch.observer/filing/0001372514-23-000159.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.